|
Session 160
Poster Abstracts
Hepatitis Antiviral Chemotherapy of HCV Infection
Wednesday, 1 - 4 pm
Poster Hall |
| 890 |
Treatment of Spanish HIV-infected Patients with Recurrent Hepatitis C Virus after Liver Transplantation with Pegylated Interferon + Ribavirin: Preliminary Results of the FIPSE OLT-HIV-05 - GESIDA 45-05 Cohort Study
Jose M. Miro*1, M Montejo2, L Castells3, A Rimola1, A Rafecas4, P Miralles5, J Fortun6, M Blanes7, M Mata8, J Pons9, and the Spanish OLT in HIV-Infected Patients Working Group
1Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; 2Hosp Cruces, Bilbao; 3Hosp Univ Vall d'Hebrón, Barcelona, Spain; 4Hosp Univ Bellvitge, Barcelona, Spain; 5Hosp Gregorio Maranon, Madrid, Spain; 6Hosp Ramon y Cajal, Madrid, Spain; 7Hosp La Fe, Valencia, Spain; 8Hosp Univ Reina Sofia, Cordoba, Spain; and 9Hosp Univ Virgen de la Arrixaca, Murcia, Spain |
891
 |
Rapid Virological Response at Week 4 Predicts Sustained Response to Pegylated Interferon + Ribavirin among HIV/HCV-co-Infected Patients
José A. Mira*1, B Valera-Bestard2, A Arizcorreta-Yarza3, M González-Serrano4, A Rivero5, I Santos6, S Vergara1, A Gutierrez-Valencia2, J Girón-González3, J Pineda1, and Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI)
1Hosp Univ de Valme, Seville, Spain; 2Hosp Univ Virgen del Rocío, Sevilla, Spain; 3Hosp Univ Puerta del Mar, Cadiz, Spain; 4Hosp Univ Virgen de la Victoria, Malaga, Spain; 5Hosp Univ Reina Sofia, Cordoba, Spain; and 6Hosp Univ de la Princesa, Madrid, Spain |
892
|
Prediction of Post-treatment Relapse Using Transcription Mediated Amplification at the End of PegIFN + Ribavirin Therapy in HIV/HCV-co-infected Patients
Beatriz Hernandez*1, A Machuca2, C Gutierrez1, N Fernandez3, C Quereda1, A Moreno1, M Perez Elias1, J Casado1, F Dronda1, and S Moreno1
1Hosp Ramon y Cajal, Madrid, Spain; 2Bayer Diagnostics, Madrid, Spain; and 3Carlos Haya Hosp, Malaga, Spain |
| 893 |
Early Therapeutic Drug Monitoring of Ribavirin Predicts Anemia and Early Virological Response in HIV-HCV-co-infected Patients
S dominguez1, B cassard2, C duvivier1, F marguet1, I boubezari1, M A valantin1, R tubiana1, K falconer1, C katlama1, and gilles peytavin*2
1Hosp Pitie-Salpetriere, Paris, France and 2Hosp Bichat-Claude Bernard, Paris, France |
| 894 |
Role of Very Early Viral Response in Prediction of Sustained Virological Response to Peg-IFN + Ribavarin in HIV/HCV-co-infected and HCV-mono-infected Individuals
D O'Shea*1, D Kevans1, H Tuite1, G Farrell1, A Grogan1, B Hynes1, S McKiernan1, S Norris1, and C Bergin1
1St James's Hosp, Dublin, Ireland |
895
|
Hepatitis C Viral Kinetics: Changes in HCV Viral Load during the First 2 Weeks Are Associated with Virologic Response but Are Not Affected by HIV Status
Mamta Jain*1, J Shelton1, A Reeck1, N Attar1, B Huet1, A Neumann2, M Gale1, and W Lee1
1Univ of Texas Southwestern Med Ctr, Dallas, US and 2Bar-Ilan Univ, Ramat-Gan, Israel |
| 896 |
HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin
Paola Nasta*, M Puoti, F Gatti, A Matti, and G Carosi
Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy |
| 897 |
Factors Associated with Virological Non-response to Peg-Interferon + Ribavirin Therapy in HIV/HCV-Co-infected Patients: The Role of Abacavir
Firouzé Bani-Sadr*1, L Denoeud1, P Morand2, F Lunel-Fabiani3, S Pol4, P Cacoub5, C Perronne6, F Carrat1, and and the ANRS HC02 – Ribavic Study team
1Groupe Hosp Univ Est, Univ Paris 6, INSERM U707, France; 2Ctr Hosp Univ Grenoble, France; 3Ctr Hosp Univ Angers, France; 4Groupe Hosp Univ Ouest, Univ Paris 5, INSERM U568, France; 5Groupe Hosp Univ Est, Univ Paris 6, France; and 6Ctr Hosp Univ Raymond Poincare, Univ de Versailles, Garches |
898
|
Antiretroviral Regimens including Tenofovir or Stavudine + Lamivudine as NRTI Backbone Are Associated with Higher Sustained Virological Response Rate to Pegylated Interferon and Ribavirin Treatment in HIV/HCV-co-infected Patients
José A. Mira*1, R Carrillo-Gómez2, A Gutierrez-Valencia3, D Merino4, A Rivero5, J Girón-González6, M Ríos-Villegas7, A Collado8, M Torres-Tortosa9, J Pineda1, and Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI)
1Hosp Univ de Valme, Sevilla, Spain; 2Hosp Univ de la Princesa, Madrid, Spain; 3Hosp Univ Virgen del Rocio, Sevilla, Spain; 4Hosp Juan Ramon Jimenez, Huelva, Spain; 5Hosp Univ Reina Sofía, Cordoba, Spain; 6Hosp Univ Puerta del Mar, Cadiz, Spain; 7Hosp Univ Virgen Macarena, Sevilla, Spain; 8Hosp Torrecardenas, Almeria, Spain; and 9Hosp Punta Europa, Cadiz, Spain |
| 899 |
Extended Treatment Does Not Reduce Relapses in HIV/HCV-co-infected Patients Treated with Pegylated Interferon + Weight-dosing Ribavirin
Marina Nunez*1, A Marino2, C Miralles3, M Berdun4, J Sola5, J Hernandez Burruezo6, M Galindo7, L Martin Carbonero1, V Soriano1, and PRESCO Study Group
1Hosp Carlos III, Madrid, Spain; 2Hosp Arquitecto Marcide, Ferrol, Spain; 3Hosp Xeral-Cies, Vigo, Spain; 4Hosp San Jorge, Huesca, Spain; 5Hosp de Navarra, Pamplona, Spain; 6Hosp Gen, Jaen, Spain; and 7Hosp Clin, Valencia, Spain |
| 900 |
Further Evidence for Invidualizing the Duration of HCV Therapy for Genotype 2/3 Disease in HIV/HCV-co-infected Patients
H Tuite, Daire O'Shea*, B Mooka, G Farrell, and C Bergin
St James's, Hosp, Dublin, Ireland |
901
|
Comparison of Hepatitis C Virus Early Kinetics in HIV/HCV-co-infected Patients Treated with Weight-based Ribavirin + Either PegIFNa-2a or PegIFNa-2b
Pablo Barreiro*, S Rodríguez-Nóvoa, P Labarga, L Martín-Carbonero, A Ruíz-Sancho, C Castellares, J González-Lahoz, and V Soriano
Hosp Carlos III, Madrid, Spain |
| 902 |
Effect of Anemia and AZT Use on Sustained Virological Response in a Trial of Pegylated Interferon + Ribavirin in HIV/HCV-co-infected Patients
Marina Nunez*1, A Ocampo2, K Aguirrebengoa3, M Cervantes4, A Pascual1, S Echeverria5, V Asensi6, P Barreiro1, J Samaniego1, V Soriano1, and PRESCO Study Group
1Hosp Carlos III, Madrid, Spain; 2Hosp Xeral-Cies, Vigo, Spain; 3Hosp de Cruces, Bilbao, Spain; 4Hosp Parc Tauli, Sabadell, Spain; 5Hosp Marques de Valdecilla, Santander, Spain; and 6Hosp Gen de Asturias, Oviedo, Spain |
| 903 |
Cut-off Values of Ribavirin Trough Concentration for Sustained Virological Response and for Hematological Toxicity in HCV/HIV-co-infected Patients Treated with RBV and Pegylated Interferon
Diego Aguilar Marucco*, D Gonzalez de Requena, L Veronese, S Bonora, A Ibanez, L Baietto, A D'Avolio, M Sciandra, A Sinicco, and G Di Perri
Univ of Turin, Italy |
904
|
Predictive Factors of Severe Toxicity Associated with Pegylated Interferon and Ribavirin Treatment in HIV/HCV-co-infected Patients
José A. Mira*1, B Valera-Bestard2, A Arizcorreta-Yarza3, D Merino4, A Rivero5, A Collado6, M Ríos-Villegas7, J Ruíz-Morales8, J Macías1, J Pineda1, and Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI)
1Hosp Univ de Valme, Sevilla, Spain; 2Hosp Univ Virgen del Rocio, Sevilla, Spain; 3Hosp Univ Puerta del Mar, Cadiz, Spain; 4Hosp Juan Ramon Jimenez, Huelva, Spain; 5Hosp Univ Reina Sofía, Cordoba, Spain; 6Hosp Torrecardenas, Almeria, Spain; 7Hosp Univ Virgen Macarena, Sevilla, Spain; and 8Hosp Univ Virgen de la Victoria, Malaga, Spain |
| 905 |
Causes of Premature Discontinuation in HIV/HCV Co-infected Patients in PRESCO, a Large Trial of Treatment with Pegylated Interferon plus Weight-based Ribavirin
Vincent Soriano*1, E Losada2, I San Joaquin3, J Guardiola4, I Santos5, J Portu6, L Bonet7, C Miralles8, P Barreiro1, M Nunez1, and on behalf of PRESCO Study Group
1Hosp Carlos III, Madrid, Spain; 2Hosp Clin Univ, Santiago; 3Hosp Clin, Zaragoza; 4Hosp de St Pau, Barcelona, Spain; 5Hosp de la Princesa, Madrid, Spain; 6Hosp Txagorritxu, Vitoria; 7Hosp Son Dureta, Mallorca; and 8Hosp Xeral-Cies, Vigo, Spain |
| 906 |
GNB3 C825T Polymorphism and Response to HCV Therapy in HCV/HIV-co-infected Patients
Jacob Nattermann*, K Bueren, H Nischalke, M Vogel, G Ahlenstiel, T Sauerbruch, U Spengler, J Rockstroh, and Kompetenznetz HIV/AIDS
Univ of Bonn, Germany |
| 907 |
Class Prediction Analyses of Gene Expression Profiles Prior to Treatment Predicts Development of Psychiatric Adverse Events of HCV Therapy among HIV-co-infected Individuals
Haniya Raza*1, D Rosenstein1, M McLaughlin2, J Yang3, R Lempicki3, M Polis2, and S Kottilil2
1Natl Inst of Mental Hlth, NIH, Bethesda, MD, US; 2Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US; and 3SAIC-Frederick/NCI-Frederick, MD, US |
|
